Prostate Cancer Management Masterclass: mCSPC Plenary Session 1
Prostate Cancer Management Masterclass: mCSPC Plenary Session 1
Dr Neal D. Shore, Assoc. Prof. Alicia Morgans
Dr Neal Shore and Assoc. Prof. Alicia Morgans present a plenary on the paradigm shift in the management of metastatic castration-sensitive prostate cancer (mCSPC).
Dr Neal D. Shore
Urologist
Carolina Urologic Research Centre and GenesisCare
United States (US)
Neal D. Shore, MD, FACS is the Medical Director for the Carolina Urologic Research Center. He practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina. Dr Shore has conducted more than 350 clinical trials, focusing mainly on GU Oncology, and serves on the Executive Boards of: Society of Urologic Oncology Board, Bladder Cancer Advocacy Network, and is Immediate Past President, Large Urology Group Practice Association. He is a founder for both: CUSP Clinical Trials Consortium, as well as for DASHKO, large urology practices data registries. He serves as the National Urology Research Director for 21st Century Oncology. He has served on the AUA Male Health Committee and the AUA Data Committee, the SITC Task Force for Prostate Cancer, the Bladder Cancer Advocacy Think Tank and the editorial boards of Reviews in Urology, Urology Times, Chemotherapy Advisor, OncLive, PLOS ONE(Academic Editor), Urology Practice, World Journal of Urology, and serves as Editor, Everyday Urology-Oncology. He has more than 200 peer reviewed publications and numerous book chapters; he performs peer review for Lancet Oncology, New England Journal of Medicine, European Urology, Journal Urology, Urology, BJUI, PCPD, and numerous other high impact scientific journals. A graduate of Duke University and Duke University Medical School, Dr Shore completed a 6-month clinical research fellowship in Pretoria, South Africa, and then completed his General Surgery/Urology training at New York Hospital Cornell Medical Center and at Memorial Sloan-Kettering Cancer Center in New York City. He is a Fellow of the American College of Surgeons.
Dr Neal D. Shore has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
Abbvie, Astellas, Amgen, AstraZeneca, Bayer, BMS, Boston Scientific, Clarity, Clovis Oncology, Cold Genesys, Dendreon, Exact Imaging, Exact Sciences, FerGene, Foundation Medicine, Genesis Care, Invitae, Janssen, Lantheus, Lilly, MDxhealth, Merck, Myovant, Myriad, Nymox, Pacific Edge, Pfizer, Phosphorous, Photocure, Propella, PreView, Sanofi Genzyme, Sema4, Speciality Networks, Sesen Bio, Telix, Tempus, Tolmar and Urogen, Vaxiion.
Assoc. Prof. Alicia Morgans
Medical Oncologist
Dana-Farber Cancer Institute
United States (US)
Dr Morgans is Genitourinary Medical Oncologist at Dana-Farber Cancer Institute, and Faculty in Medicine at Harvard Medical School in Boston, MA. She completed medical school and residency at the University of Pennsylvania School of Medicine, fellowship in Hematology/Oncology at Harvard’s Dana Farber Cancer Institute and Massachusetts General Hospital Cancer Center in Boston and earned a Master of Public Health at Vanderbilt University. Dr Morgans treats patients with prostate, bladder, and testicular cancer, and her research assesses complications of advanced prostate cancer survivorship and patient-centered treatment decision-making in advanced prostate cancer.
Assoc. Prof. Alicia Morgans has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
AAA, Astellas, AstraZeneca, Bayer, Exelixis, Janssen, Myovant, Novartis, Pfizer, Sanofi and Telix.
Webinar |
35 min
|
Dec 2020
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
Was valuable to me:
1/4
Has improved my knowledge of this topic:
2/4
Is likely to change my clinical practice:
3/4
Was balanced and unbiased:
4/4
download resources
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
Was valuable to me:
1/4
Has improved my knowledge of this topic:
2/4
Is likely to change my clinical practice:
3/4
Was balanced and unbiased:
4/4
Prostate Cancer Management Masterclass: mCSPC Plenary Session 1
Prof. Alicia Morgans, co-hosted, along with Dr Neal Shore, Prof. Tanya Dorff and Prof. Evan Yu, a highly interactive GU CONNECT Virtual Masterclass on Prostate Cancer Management.
In this first plenary Dr Neal Shore and Prof. Alicia Morgans, present a Paradigm shift in the management of metastatic castration-sensitive prostate cancer (mCSPC).
In plenary 2 Prof. Tanya Dorff and Prof. Evan Yu present “Next-generation” sequencing of therapy for Castration-Resistant Prostate Cancer (CRPC).
Watch the video and download the slides.
GU CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from AstraZeneca, Bayer and Eisai Europe Limited.